Insights
Search Results
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
News Articles
9.11.26
Wilson Sonsini Attorneys Named Among 2027 Lawdragon 500 Leading Litigators in America
On September 11, 2026, Lawdragon named 33 Wilson Sonsini attorneys to its 2027 edition of Lawdragon 500 Leading Litigators in America. The lawyers featured in the guide represent the best litigators in the U.S. in antitrust, intellectual property, white collar and investigations, securities and corporate governance litigation, and a vast array of class actions, product liability, and other complex civil litigation.
Client Highlights
9.03.26
Wilson Sonsini Advises Hugging Face on $12.9 Billion Acquisition by NVIDIA
On September 3, 2026, NVIDIA announced that it has agreed to acquire open-source AI platform Hugging Face for $12.9 billion. Together, NVIDIA and Hugging Face plan to scale Hugging Face’s platform, strengthen its infrastructure, and expand access to AI for developers and institutions worldwide. Wilson Sonsini Goodrich & Rosati advised Hugging Face on the transaction.
News Articles
8.26.26
Wilson Sonsini Attorneys Appointed to American Bar Association Leadership Roles
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, is proud to announce that 14 of its attorneys have been appointed to leadership roles within the American Bar Association (ABA) for the 2026-2027 term. Of these, 12 will serve in the ABA’s Antitrust Law Section, one will serve in the ABA’s Business Law Section, and one will serve in the ABA’s Intellectual Property Law Section. The appointments reflect the firm's role in the ongoing development of policy and practice across these fields.
Client Highlights
8.06.26
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.
Client Highlights
8.05.26
Firm Advises DISA Technologies on Launch of DISA Uranium Corporation
On August 4, 2026, DISA® Technologies, a uranium recovery and production company, announced the formation of DISA Uranium™ Corporation, a new American company built to recover and produce domestic uranium and remediate the nation's legacy uranium sites. In connection with its launch, DISA Uranium has entered into a definitive agreement to acquire IsoEnergy's Utah uranium portfolio of permitted, past-producing mines and projects—giving DISA Uranium a scaled conventional resource base to pair with its proprietary processing technology and the only U.S. Nuclear Regulatory Commission license of its kind. Wilson Sonsini Goodrich & Rosati advised DISA on the transaction.
Client Highlights
8.03.26
Wilson Sonsini Advises Firefly Bio on $1 Billion Acquisition by Johnson & Johnson
On July 29, 2026, Johnson & Johnson announced the completion of its acquisition of Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances the company’s ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
7.09.26
Wilson Sonsini Advises Beam Benefits on Acquisition by Principal Financial Group
On July 7, 2026, Principal Financial Group announced an agreement to acquire Beam Benefits, an employee benefits company serving more than 25,000 small businesses. Principal currently serves 180,000 employers, providing comprehensive retirement, benefits, and business owner solutions. The acquisition is expected to close in the latter half of 2026, subject to the completion of customary closing conditions and regulatory approvals. Wilson Sonsini Goodrich & Rosati advised Beam Benefits on the transaction.
Alerts
6.26.26
FTC Conditions Aurobindo’s Acquisition of Lannett on Divestiture of Four Generic Drugs
On June 18, 2026, the Federal Trade Commission (FTC) announced that it would allow Aurobindo Pharma Limited’s approximately $250 million acquisition of Lannett Company, Inc. to proceed, subject to a proposed consent order requiring Aurobindo to divest four overlapping generic pharmaceutical products to Quagen Pharmaceuticals, LLC. The Commission voted 2-0 to issue an administrative complaint and accept the consent agreement for a 30-day public comment period.
Client Highlights
6.24.26
Wilson Sonsini Advises Saturnus Bio on Strategic Collaboration with Merck KGaA, Darmstadt, Germany
On June 23, 2026, Merck KGaA, Darmstadt, Germany, a leading global science and technology company, announced a strategic collaboration with Versant Ventures to launch Saturnus Bio, a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet need. Wilson Sonsini Goodrich & Rosati advised Saturnus Bio on the transaction.
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes: